Recent studies have confirmed the potential role of human leukocyte antigen in its pathogenesis.[10] IL-6, which is shown to be expressed in TA arterial lesions, influences the function of many types of cells and has a role in vascular inflammation.[11,12] The preliminary studies and case reports suggested that tocilizumab, a humanized anti-IL-6 receptor antibody, may be an option for refractory TA patients.[13–16]. This evidence concerns the gene IL6 and Takayasu arteritis.